The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
The liquid biopsy era is finally here.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.